First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (TRAXV) — Cash Flow-to-Debt Ratio
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (TRAXV) has a Cash Flow-to-Debt Ratio of -0.98x as of March 2026, meaning its operating cash flow of $-32.56 Million could theoretically repay -1% of its total liabilities ($33.11 Million) in one year. See financial agility of First Tracks Biotherapeutics, Inc. Ordin to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued Cash Flow-to-Debt Ratio (2023–2024)
Historical debt coverage capacity for First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued across 2 annual periods. For the full cash flow conversion analysis, see TRAXV cash generation efficiency.
Annual Cash Flow-to-Debt Ratio for First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (2023–2024)
Year-by-year debt coverage analysis for First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -2.50x | $-125.81 Million | $50.30 Million | ▲ +7.9% |
| 2023 | -2.71x | $-93.00 Million | $34.26 Million | — |